GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (FRA:5Y6) » Definitions » Research & Development

Compass Pathways (FRA:5Y6) Research & Development : €86.26 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Compass Pathways's Research & Development for the three months ended in Mar. 2024 was €22.91 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €86.26 Mil.


Compass Pathways Research & Development Historical Data

The historical data trend for Compass Pathways's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Research & Development Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 11.31 19.21 38.96 61.41 80.25

Compass Pathways Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.78 18.29 20.17 24.89 22.91

Compass Pathways Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €86.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compass Pathways  (FRA:5Y6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Compass Pathways Research & Development Related Terms

Thank you for viewing the detailed overview of Compass Pathways's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways (FRA:5Y6) Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways (FRA:5Y6) Headlines

No Headlines